Clinical Trials

Zynerba Pharmaceuticals (ZYNE +7.6%) initiates a Phase 2 clinical trial, STOP, assessing lead product candidate ZYN002 for the treatment of knee pain due to osteoarthritis, an affliction affecting 31M Americans. STOP is a double-blind placebo-controlled study that will enroll up to 300 patients. After a baseline phase, subjects will be randomized to receive either 125 […]

by

File photo by Tony Avelar/The Christian Science Monitor Mahmoud ElSohly oversees acres of marijuana plants in the deep south, a swath of the country the tide of medical marijuana legalization has yet to touch. But he’s not running an illegal operation — he’s a professor of pharmaceutics and head of the marijuana program at the […]

by

Mahmoud ElSohly oversees acres of marijuana plants in the deep south, a swath of the country the tide of medical marijuana legalization has yet to touch. But he’s not running an illegal operation — he’s a professor of pharmaceutics and head of the marijuana program at the University of Mississippi, which holds an exclusive contract with the […]

by

DEVON, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated a Phase 2 clinical trial, STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis (OA)), of ZYN002 cannabidiol […]

by

ONTARIO, CANADA — Patients with epilepsy frequently experiment with cannabis and most report experiencing subjective benefits following their use of the substance, according to data published online ahead of print in the journal Epilepsy Behavior. Canadian researchers surveyed the experiences of over 300 adult patients admitted to an epilepsy monitoring unit over a 14-month period. More […]

by

There’s no denying the immense medicinal value that cannabis has for certain disorders and diseases, from post-traumatic stress disorder to glaucoma, but, the benefits that cannabis may or may not provide to someone suffering from autism is one area that has remained quite gray. Earlier this year, we took an in-depth look at a handful […]

by

A cannabis leaf. Photo: Jon Richfield via Wikimedia Commons. JNS.org – An Israeli pediatrician has launched a clinical trial to study the effects of medical cannabis on autistic children and adults, Haaretz reported. Dr. Adi Eran, head of the pediatric neurology department at Shaare Zedek Medical Center in Jerusalem, is obtaining permits from Israel’s Ministry of Health […]

by

Israeli Doctor to Use Medical Cannabis to Treat Autism in First-of-Its-Kind Study, Report   In view of evidence that cannabinoids can help improve the quality of life of autistic people, an Israeli pediatrician has launched a first of… read more at: http://jewishbusinessnews.com/2016/08/30/israeli-doctor-to-use-medical-cannabis-to-treat-autism-in-first-of-its-kind-study-report/

by

Image Source: Getty Images. Unlike most biopharma stocks, GW Pharmaceuticals (NASDAQ:GWPH), a British company developing marijuana-based medicines, has turned in a stellar 2016. Specifically, the company’s shares are now up by nearly 20% year to date and have simply crushed the performance of the iShares Nasdaq Biotechnology ETF: IBB data by YCharts. GW’s unusual strength […]

by

As more and more states across the US push towards marijuana reform, investors are increasingly seeing the plant and its chemical compounds as an emerging industry; ripe for the taking in what is fast becoming a multi-billion dollar business . Over the years they’ve garnered a little action in the OTC market, but we’re taking a […]

by

By Dania Duran As more and more states across the US push towards marijuana reform, investors are increasingly seeing the plant and its chemical compounds as an emerging industry, ripe for the taking in what is fast becoming a multi-billion dollar business. Over the years, they’ve garnered a little action in the OTC market, but […]

by

By Dania Duran As more and more states across the US push towards marijuana reform, investors are increasingly seeing the plant and its chemical compounds as an emerging industry, ripe for the taking in what is fast becoming a multi-billion dollar business. Over the years, they’ve garnered a little action in the OTC market, but […]

by